Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
July 29 2019 - 7:00AM
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX)
today announced that Eyal Rubin has been appointed to serve as the
Company’s new Senior Vice President and Chief Financial Officer,
effective September 22, 2019. Yossi Maimon will continue
to work with the Company’s finance and accounting teams to ensure a
smooth transition of the Company’s financial and accounting
functions until Mr. Rubin begins.
“I am very happy to introduce Eyal to the Protalix team where he
will bring valuable financial and accounting experience and
knowledge,” said Dror Bashan, Protalix’s President and Chief
Executive Officer. “We wish Yossi success in his future
endeavors. Yossi has played a critical role in Protalix’s
leadership enabling Protalix to advance our pipeline development
during his tenure. On behalf of Protalix and its Board of
Directors, I would like to thank Yossi for his dedication and
leadership.”
“It has been my privilege to be part of the Protalix team,”
commented Yossi Maimon, Protalix’s outgoing Chief Financial
Officer. “After almost thirteen years, it is time for me to
pursue new opportunities. I am deeply grateful to Protalix,
its employees and its Board of Directors, and continue to believe
that the products in development are promising.”
“I am excited to join Protalix as we move towards applying for
accelerated approval of PRX-102,” said Mr. Rubin. “I am
looking forward to joining Protalix’s talented management team and
taking part in the progress of Protalix’s future development.”
Mr. Rubin brings to Protalix more than 20 years of finance and
capital markets experience, an extensive background in financial
planning and operations, management and strategy and a deep
knowledge of the biotechnology and pharmaceutical industries.
He most recently served as Executive Vice President and Chief
Financial Officer of BrainStorm Cell Therapeutics Inc., a publicly
traded biotechnology company, where he was responsible for all
corporate finance, accounting and investor relations
activities. Prior to his role at BrainStorm, Mr. Rubin served
at Teva Pharmaceutical Industries Ltd. in several roles, most
recently as Vice President, Head of Corporate Treasury. In
this role, Mr. Rubin was responsible for Teva’s cash operations and
cash management, as well as Teva’s equity and debt capital markets
transactions. Mr. Rubin holds a BA in Financing and IT
Systems from the College of Management, Israel, where he graduated
Summa Cum Laude with a specialization in Financing and IT Systems,
and an MBA from Bar-Ilan University, Israel, where he graduated
Summa Cum Laude with a specialization in Finance.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based
expression system, ProCellEx®. Protalix’s unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.
Protalix’s first product manufactured by ProCellEx,
taliglucerase alfa, was approved for marketing by the
U.S. Food and Drug Administration (FDA) in May 2012 and,
subsequently, by the regulatory authorities of other countries.
Protalix has licensed to Pfizer Inc. the worldwide
development and commercialization rights for taliglucerase alfa,
excluding Brazil, where Protalix retains full rights.
Protalix’s development pipeline includes the following
product candidates: pegunigalsidase alfa, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry
disease; OPRX-106, an orally-delivered anti-inflammatory treatment;
alidornase alfa for the treatment of Cystic Fibrosis; and others.
Protalix has partnered with Chiesi Farmaceutici S.p.A., both
in the United States and outside the United States, for the
development and commercialization of pegunigalsidase alfa.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms “expect,”
“anticipate,” “believe,” “estimate,” “project,” “plan,” “should”
and “intend” and other words or phrases of similar import are
intended to identify forward-looking statements. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual future experience and
results to differ materially from the statements made. The
statements in this press release are valid only as of the date
hereof and we disclaim any obligation to update this information,
except as may be required by law.
Investor Contact
Alan Lada, Vice President Solebury Trout 617-221-8006
alada@soleburytrout.com
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2023 to Apr 2024